Zajac

AEOVIAN PHARMACEUTICALS DOSES FIRST PARTICIPANTS IN PHASE 1 CLINICAL TRIAL, STRENGTHENS LEADERSHIP TEAM AND RAISES ADDITIONAL $50 MILLION FINANCING

Retrieved on: 
Thursday, March 28, 2024
Xenon, TSC, Epilepsy, Alexion Pharmaceuticals, Patient, Sale, Investment, Therapy, Melinda French Gates, Jazz Pharmaceuticals, Genetic disorder, Ageing, CIO, Notifiable disease, Biotechnology, Yale University, CNS, NIH, Zajac, University of Bristol, Honours degree, UCSF, Drug discovery, Evotec, GW Pharmaceuticals, Genetic distance, DSM-IV codes, Wesleyan University, Growth, CFO, BIO, Record, Bachelor of Science, Morgan Stanley, Former, Pharmaceutical industry

BERKELEY, Calif., March 28, 2024 /PRNewswire/ -- Aeovian Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel and highly selective therapeutics that potently inhibit the mTORC1 pathway, today announced that it has dosed the first cohort of participants in a Phase 1 clinical trial for its lead development candidate AV078, a first-in-class CNS penetrant selective mTORC1 inhibitor. Supporting this transition into the clinic, the company has also expanded its leadership team with the appointment of seasoned industry veterans William Greene, M.D., Chief Investment Officer at Hevolution, and Justin Gover, former Chief Executive Officer of GW Pharmaceuticals, to the company's Board of Directors, and appointed Micah Zajic as Chief Financial Officer. The company also recently completed a $50 million financing, led by Hevolution.

Key Points: 
  • Aeovian has assembled a compelling platform for the development of selective mTORC1 inhibitors," said Dr. Greene, CIO at Hevolution.
  • In the $50M financing, Hevolution was joined by existing investors Apollo Health Ventures, Sofinnova Investments, venBio, Evotec and b2venture.
  • This financing will support the completion of the Phase 1 clinical trial in healthy volunteers and prepare for the start of a subsequent Phase 2 clinical trial in adult and pediatric patients with TSC refractory epilepsy.
  • As CEO, he built and led Iconic Therapeutics through discovery, clinical development, and venture financing, which culminated in a successful sale of the company.

LEXEO Therapeutics Appoints Micah Zajic as Chief Financial Officer and Paula H. J. Cholmondeley as Board of Directors Audit Committee Chair

Retrieved on: 
Thursday, January 5, 2023
Bank, National Association, Central nervous system, Morgan Stanley, Therapy, AAV, NACD, Audit committee, National Association of Corporate Directors, CNS, Bank OZK, Growth, NYSE, Zajac, Audit, Terex, Alexion Pharmaceuticals, Genetics, Corporation, Management

Cholmondeley to its Board of Directors as Audit Committee Chair.

Key Points: 
  • Cholmondeley to its Board of Directors as Audit Committee Chair.
  • Micah Zajic has been appointed Chief Financial Officer at LEXEO.
  • Mr. Zajic brings nearly 20 years of experience in biotech corporate development, healthcare capital markets and investment banking to LEXEO.
  • Mr. Zajic most recently served as Chief Financial Officer at SQZ Biotechnologies (NYSE).

SQZ Biotechnologies Reports Second Quarter 2022 Financial Results and Recent Portfolio Updates

Retrieved on: 
Thursday, August 4, 2022
Research, Infectious Diseases, Genetics, Clinical Trials, Biotechnology, Health, Other Science, Science, Oncology, APC, U.S. Securities and Exchange Commission, Immune tolerance, Risk, TAC, Cell, NYSE, CEO, Autoimmunity, POC, Private Securities Litigation Reform Act, Leadership, Degenerative disease, Confidentiality, Annual report, Neoplasm, Patient, Hospital, COVID-19, Doctor of Philosophy, Infection, Therapy, Zajac, Fast track (FDA), Research, SQZ, Pharmaceutical industry

SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today reported second quarter 2022 financial results and recent portfolio updates.

Key Points: 
  • SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today reported second quarter 2022 financial results and recent portfolio updates.
  • We also highlighted the progress in developing our Point-of-Care manufacturing system which supports our long-term vision to enable broad accessibility of cell therapies.
  • Finally, I am delighted by the addition of our newest senior team member, Dr. Marshelle Smith Warren as our Chief Medical Officer, and the elevation of Micah Zajic to Chief Financial Officer.
  • Actual results could differ from those projected in any forward-looking statements due to several risk factors.

SQZ Biotechnologies Appoints Micah Zajic as Chief Financial Officer

Retrieved on: 
Monday, July 11, 2022
Research, Infectious Diseases, Clinical Trials, Biotechnology, Other Health, Health, Other Science, Science, Oncology, Private Securities Litigation Reform Act, Micah, Georgetown University, Confidentiality, COVID-19, Biotechnology, CEO, Risk, Annual report, CFO, BA, Economics, NYSE, Investment banking, Therapy, SQZ, Doctor of Philosophy, Hospital, Infection, Janssen Pharmaceuticals, U.S. Securities and Exchange Commission, Degenerative disease, Zajac, Accounting, Autoimmunity, Â, Immune tolerance, Patient, Alexion Pharmaceuticals, Cell, Pharmaceutical industry, Management

SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it has appointed Micah Zajic, as the companys Chief Financial Officer, effective immediately.

Key Points: 
  • SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it has appointed Micah Zajic, as the companys Chief Financial Officer, effective immediately.
  • Mr. Zajic has served as the companys Chief Business Officer since October 2020 and brings nearly 20 years of biotechnology and capital markets experience to the role.
  • I am excited to continue working closely with Micah as we work to drive patient impact with SQZs cell therapies
    Mr. Zajic joined SQZ Biotechnologies as Chief Business Officer in October 2020 where he develops and maintains key strategic relationships with current and potential external partners.
  • SQZ Biotechnologies Company is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies for patients around the world.

Lumeon Announces Appointment of Tom Zajac to Board of Directors as Executive Chair

Retrieved on: 
Tuesday, January 26, 2021
Data management, Health, Technology, Hospitals, Managed care, Software, General Health, Companies, Eindhoven, Philips, Videotelephony, Elsevier, Zajac, Brands, Consumer electronics

Lumeon , the leader in care journey orchestration, today announced the appointment of Tom Zajac to the Lumeon Board of Directors, effective December 20, 2020.

Key Points: 
  • Lumeon , the leader in care journey orchestration, today announced the appointment of Tom Zajac to the Lumeon Board of Directors, effective December 20, 2020.
  • Zajac will serve as executive chair, supporting Lumeon as it continues its growth in helping healthcare systems develop and scale new models of delivery.
  • We are pleased to welcome Tom Zajac to the Lumeon board, said Lumeon Founder and CEO Robbie Hughes.
  • Zajac previously served as CEO of Population Health at Philips, president and CEO of Wellcentive, chief customer officer at Elsevier, and CEO of CareScience.

Precisely Expands Leadership with Appointment of COO, General Counsel

Retrieved on: 
Thursday, May 28, 2020
Software, Technology, Other Technology, Data management, ClickSoftware Technologies, salesforce.com, Zajac, General counsel, Computer companies, Business, Computing

Precisely has 2,000 employees and 12,000 customers in more than 100 countries, including 90 of the Fortune 100.

Key Points: 
  • Precisely has 2,000 employees and 12,000 customers in more than 100 countries, including 90 of the Fortune 100.
  • Yau will play an instrumental role in Preciselys evolution, helping guide the company and product strategy as it expands its leadership position in data integrity.
  • Zajac joins as General Counsel, where he will head the companys global legal function and oversee its global compliance programs.
  • Prior to joining Precisely, Zajac served as SVP, General Counsel, and Corporate Secretary for ClickSoftware, which was acquired by Salesforce.com in 2019.